U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Jun 26 22:59:22 UTC 2021
Edited
by admin
on Sat Jun 26 22:59:22 UTC 2021
Protein Sub Type
Sequence Type COMPLETE
Record UNII
Z3LSI83ND8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5-HYDROXYTRYPTAMINE RECEPTOR 6
Common Name English
5-HT-6
Common Name English
SEROTONIN RECEPTOR 6
Common Name English
HTR6
Common Name English
Code System Code Type Description
FDA UNII
Z3LSI83ND8
Created by admin on Sat Jun 26 22:59:23 UTC 2021 , Edited by admin on Sat Jun 26 22:59:23 UTC 2021
PRIMARY
UNIPROT
P50406
Created by admin on Sat Jun 26 22:59:23 UTC 2021 , Edited by admin on Sat Jun 26 22:59:23 UTC 2021
PRIMARY
From To
1_99 1_180
Related Record Type Details
INHIBITOR -> TARGET
INHIBITOR -> TARGET
ANTAGONIST->TARGET
INHIBITOR -> TARGET
Full antagonist SAM-760 completed phase I trials with no adverse effects at doses of up to 50 mg daily. Pfizer terminated a phase II trial after SAM-760 30 mg/day failed to produce an improvement in cognition in patients already taking a stable dose of donepezil.
INHIBITOR -> TARGET
ANTAGONIST
INHIBITOR -> TARGET
INHIBITOR
Ki
INHIBITOR -> TARGET
Phase III trials showed weak efficacy as compared to phase II trials, which may be explained by underdosing. Phase II trials evaluated the use of 90 mg daily (30 mg TID) as an adjunct to an acetylcholinesterase inhibitor. Study investigators decided to lower the dose of idalopirdine in phase III trials based on receptor occupancy analysis conducted by PET scan
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR -> TARGET
INHIBITOR
Ki
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL